Clinical Trial Update: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

A phase 3 trial to assess efficacy and safety of Afimkibart (RO7790121) in moderately to severely active ulcerative colitis; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Afimkibart (RO7790121)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Moderately to Severely Active Ulcerative Colitis | Phase 3 | Status: RECRUITING